未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy基于炎症选择最优免疫疗法：用于PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌：帕博利珠单抗单药治疗与联合化疗免疫疗法
Kunimatsu, Yusuke; Nishioka, Naoya; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ishida, Masaki; Kijima, Takashi; Takayama, Koichi 分享 收藏 Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapyKawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi 分享 收藏 分享 收藏 Chemoimmunotherapy versus pembrolizumab as a fi rst-line treatment for patients with advanced non-small cell lung cancer and high PD-L1 expression: Focus on the role of performance status化疗免疫疗法与帕博利珠单抗作为PD-L1高表达晚期非小细胞肺癌患者一线治疗的选择：聚焦于体力状况的作用Yamada, T.; Morimoto, K.; Kawachi, H.; Tamiya, M.; Negi, Y.; Goto, Y.; Nakao, A.; Shiotsu, S.; Tanimura, K.; Okada, A.; Date, K.; Harada, T.; Chihara, Y.; Hasegawa, I.; Tamiya, N.; Kijima, T.; Takayama, K. 分享 收藏 Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohortTachibana, Yusuke; Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi 分享 收藏 CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational studyKataoka, Nobutaka; Katayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Yamada, Takahiro; Hiranuma, Osamu; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Takayama, Koichi 分享 收藏 Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter studyNishioka, Naoya; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Masui, Taiki; Sai, Natsuki; Ishida, Masaki; Katayama, Yuki; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi 分享 收藏 Impact of proton pump inhibitor on ICI with or without chemotherapy for NSCLC with high PD-L1 TPSSawada, Ryo; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Kijima, Takashi; Takayama, Koichi 分享 收藏 Association between clinical characteristics and treatment outcome of immune checkpoint inhibitor with or without chemotherapy in elderly non-small cell lung cancer patients with high PD-L1 expressionKawachi, Hayato; Takei, Shota; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Kijima, Takashi; Takayama, Koichi 分享 收藏 Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older PatientsOnoi, Keisuke; Yamada, Tadaaki; Morimoto, Kenji; Kawachi, Hayato; Tsutsumi, Rei; Takeda, Takayuki; Okada, Asuka; Tamiya, Nobuyo; Chihara, Yusuke; Shiotsu, Shinsuke; Takemura, Yoshizumi; Yamada, Takahiro; Hasegawa, Isao; Katayama, Yuki; Iwasaku, Masahiro; Tokuda, Shinsaku; Takayama, Koichi 分享 收藏 Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective StudyKatayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Fujii, Hiroyuki; Morita, Satomi; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Hiranuma, Osamu; Yamada, Takahiro; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Iwasaku, Masahiro; Tokuda, Shinsaku; Tanaka, Noriyuki; Miyagawa-Hayashino, Aya; Takayama, Koichi 分享 收藏 Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%免疫检查点抑制剂联合化疗对TPS ≥ 50% 的老年非小细胞肺癌PD-L1预后的影响Takei, Shota; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi 分享 收藏 Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance StatusMorimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Nishioka, Naoya; Katayama, Yuki; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi 分享 收藏 Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS I50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort studyKawachi, H.; Yamada, T.; Tamiya, M.; Negi, Y.; Goto, Y.; Nakao, A.; Shiotsu, S.; Tanimura, K.; Takeda, T.; Okada, A.; Harada, T.; Date, K.; Chihara, Y.; Hasegawa, I.; Tamiya, N.; Iwasaku, M.; Tokuda, S.; Kijima, T.; Takayama, K. 分享 收藏 分享 收藏 TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational StudyKatayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Fujii, Hiroyuki; Morita, Satomi; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Hiranuma, Osamu; Yamada, Takahiro; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Yoshimura, Akihiro; Iwasaku, Masahiro; Tokuda, Shinsaku; Kim, Young Hak; Takayama, Koichi 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
